Read by QxMD icon Read


Carla Felice, Daniela Pugliese, Luigi Giovanni Papparella, Fabrizio Pizzolante, Eugenia Onori, Antonio Gasbarrini, Gian Lodovico Rapaccini, Luisa Guidi, Alessandro Armuzzi
Spondyloarthritis (SpA) is the most common extra-intestinal manifestation in patients with inflammatory bowel diseases (IBD). Articular disorders may also appear as "paradoxical" effects during biologic therapy with anti-tumor necrosis factor (TNF). Areas covered: In this narrative review, we report the current knowledge about the pathogenesis, the diagnosis and the therapeutic management of articular diseases occurring in patients with IBD. Expert commentary: Evidence-based recommendations for the management of IBD-associated SpA and paradoxical arthritis are lacking...
August 17, 2018: Expert Review of Clinical Immunology
Ahmed Al-Dwairi, Mohammad Alqudah, Othman Al-Shboul, Mahmoud Alfaqih, Dana Alomari
Inflammatory bowel disease (IBD) is a chronic incurable condition characterized by relapsing inflammation of the gut. Intestinal smooth muscle cells (SMCs) are affected structurally and functionally during IBD due to excessive production of different inflammatory mediators. Metformin is a widely used antidiabetic agent known to exert several anti-inflammatory effects in different tissues independently from its hypoglycemic effect. The aim of the present study was to investigate the effect of metformin on expression and secretion of different cytokines and chemokines from mouse colon SMCs (CSMCs) following induction of inflammation with lipopolysaccharide (LPS) in vitro ...
August 2018: Experimental and Therapeutic Medicine
Amanda Ricciuto, Jasbir Dhaliwal, Thomas D Walters, Anne M Griffiths, Peter C Church
Background and aims: We undertook a systematic review and meta-analysis examining the effectiveness of therapeutic drug monitoring (TDM) to improve clinical outcomes in anti-TNF-treated IBD patients. Methods: We searched MEDLINE, Epub Ahead of Print, EMBASE and Cochrane through October 2017 for randomized trials (RCTs) and cohort studies comparing proactive or reactive TDM to each other or empiric care. Outcomes included clinical remission (primary), clinical relapse, endoscopic remission, anti-TNF response durability, cost and adverse events (secondary)...
August 10, 2018: Journal of Crohn's & Colitis
Fu Yuan Yang, Rui Chen, Xiaohu Zhang, Biao Huang, Lai Ling Tsang, Xican Li, Xiaohua Jiang
Mesenchymal stem cell (MSC)-based cell therapy has been demonstrated as a promising strategy in the treatment of inflammatory bowel disease (IBD), which is considered an immune disease. While the exact mechanisms underlying the therapeutic effect of MSCs are still unclear, MSCs display anti-inflammatory and immunomodulatory effects by interacting with various immunoregulatory cells. Our previous studies have shown that MSCs can be preconditioned and deconditioned with enhanced cell survival, differentiation and migration...
August 10, 2018: Cell Transplantation
Yunbing Wu, Wei Qiu, Xinwei Xu, Jingjing Kang, Jingyan Wang, Yingying Wen, Xudong Tang, Yongmin Yan, Hui Qian, Xu Zhang, Wenrong Xu, Fei Mao
Exosomes released from mesenchymal stem cells (MSCs) have an anti-inflammatory effect and can repair tissue injuries. Ubiquitination plays an important role in the regulation of various biological functions, including the regulation of inflammation. However, it remains unknown whether exosomes from human umbilical cord mesenchymal stem cells (hucMSC-ex) may cure the mice of DSS-induced inflammatory bowel disease (IBD) through the ubiquitin modification. In this study, we aimed to investigate the therapeutic effect and probe the mechanism relating to ubiquitination underlying the hucMSC-ex treatment in DSS-induced IBD of mice...
2018: American Journal of Translational Research
Murray Lindsay Barclay, Shwan Karim, Esther Theodora Johanna Helms, Paula Elizabeth Keating, Barry Hock, Lisa Katrina Stamp, Michael Schultz
BACKGROUND AND AIM: We aimed to correlate IBD disease activity in New Zealand patients with trough concentrations of infliximab and adalimumab using a locally developed enzyme-linked immunosorbent assay (ELISA), and anti-drug antibodies (ADA) using competitive-binding ELISA and homogeneous mobility shift assay (HMSA), to establish threshold concentrations. METHODS: Patients with ulcerative colitis (UC) and Crohn's disease (CD) from Christchurch and Dunedin on anti-TNF drugs >12 weeks were enrolled...
August 8, 2018: Internal Medicine Journal
Michael G Kattah, Jeffrey M Milush, Trevor Burt, Robert P McCabe, Michael I Whang, Averil Ma, Uma Mahadevan
The original version of this article contained an error in Fig. 2, in which part of the text in the legend was omitted. This has now been corrected in the PDF and HTML versions of the paper.Furthermore, the figure legends were missing for the Supplementary figure files. The HTML has now been updated to include a corrected version of the Supplementary Information.
July 31, 2018: Clinical and Translational Gastroenterology
Mariangela Allocca, Federica Furfaro, Gionata Fiorino, Daniela Gilardi, Silvia D'Alessio, Silvio Danese
A considerable percentage of patients with ulcerative colitis (UC) do not respond to therapies, including anti-tumor necrosis factor (TNF) drugs and vedolizumab, or lose response over time. Hence the continuing need to find new therapeutic strategies and novel drugs to control this chronic debilitating disease. Increased levels of interleukin (IL)-23 and T helper (Th) 17 cell cytokines have been found in intestinal mucosa, plasma, and serum of patients with inflammatory bowel disease (IBD). IL23-blocking has been shown to reduce the severity of inflammation in experimental colitis...
February 2018: Best Practice & Research. Clinical Gastroenterology
Laura Núñez-Gómez, Francisco Mesonero-Gismero, Agustín Albillos-Martínez, Antonio López-Sanromán
Anti-tumor necrosis factor agents (anti-TNF) drugs are commonly used in patients with inflammatory bowel disease (IBD) and have proven effective in both induction and maintenance therapy in luminal Crohn's disease and ulcerative colitis. Their efficacy has also been proven in fistulising perianal Crohn's disease. However, the evidence in other scenarios, such as stricturing, penetrating and non-fistulising perianal Crohn's disease, extraintestinal IBD manifestations and ileoanal reservoir complications, is not as robust...
July 24, 2018: Gastroenterología y Hepatología
Carlos Taxonera, Ángel Ponferrada, Sabino Riestra, Fernando Bermejo, Cristina Saro, María Dolores Martín-Arranz, José Luis Cabriada, Manuel Barreiro-de Acosta, María Luisa de Castro, Pilar López-Serrano, Jesús Barrio, Cristina Suarez, Eva Iglesias, Federico Argüelles-Arias, Isabel Ferrer, Ignacio Marín-Jiménez, Alejandro Hernández-Camba, Guillermo Bastida, Manuel Van Domselaar, Pilar Martínez-Montiel, David Olivares, Montserrat Rivero, Luis Fernandez-Salazar, Óscar Nantes, Olga Merino, Cristina Alba, Javier P Gisbert
Aim: To assess the likelihood of detecting latent tuberculosis infection (LTBI) by the positive conversion of a serial tuberculin skin test (TST) at 1 year in inflammatory bowel disease (IBD) patients with negative baseline 2-step TST. Methods: In this multicentre prospective cohort study we evaluated rate and predictors of conversion of TST at 1 year in patients with negative baseline TST. We also evaluated management of patients who had a positive TST at baseline or a conversion at 1 year...
July 21, 2018: Journal of Crohn's & Colitis
Shiying Zhang, Jing Fu, Belgin Dogan, Ellen J Scherl, Kenneth W Simpson
5-aminosalicylate (5-ASA) is widely prescribed for the treatment of inflammatory bowel disease (IBD) and prevention of inflammation-associated colorectal cancer (CRC). Its clinical effect is widely attributed to modulation of host inflammatory responses. However, the recent association of intestinal dysbiosis and selective enrichment in Escherichia coli in patients with IBD and CRC raises the possibility that 5-ASA might also affect the enteric microflora. The aim of this study was to investigate the effect of 5-ASA on the growth and virulence of E...
July 26, 2018: Journal of Antibiotics
Shingo Kato, Akira Ishibashi, Kaori Sugiura, Kazuhito Kani, Tomonari Ogawa, Hajime Hasegawa, Koji Yakabi
BACKGROUND: Idiopathic acute-on-chronic inflammation in the gastrointestinal tract is an etiology of inflammatory bowel disease (IBD). Granulocyte and monocyte adsorptive apheresis (GMA) is a nonpharmacological treatment tool for patients with IBD. Here, we present a review of the positioning and possibilities of GMA for patients with IBD. SUMMARY: GMA decreases inflammatory cytokines and upregulates regulatory T cells. Intensive GMA is significantly more effective than weekly GMA in patients with IBD...
2018: Contributions to Nephrology
Francisco J Melo, Sofia Magina
Tumor necrosis factor alpha inhibitors (anti-TNF-α) completely revolutionized the treatment of inflammatory bowel disease (IBD). However, anti-TNF-α-induced cutaneous side effects have been increasingly reported in the literature. Particularly, psoriasis and the recently recognized psoriasiform lesions are of particular concern, as anti-TNF-α agents are also used in the treatment of psoriasis, seemingly reflecting an immunological paradox. The clinical management of these cutaneous lesions is particularly challenging, owing to the potential need of anti-TNF-α discontinuation and scarcity of other therapeutic options...
July 20, 2018: International Journal of Dermatology
Florian Bär, Thomas Krause, Andreas Stallmach, Niels Teich, Christian Maaser, Jochen Maul, Ulf Helwig, Klaus Fellermann, Jürgen Büning
Background and Aims: In Crohn's disease (CD) patients still remain refractory to current regimens, including biologicals. Previous data from small single-center studies indicated cyclophosphamide pulse therapy (CPT) to be effective for induction of remission at least in steroid-refractory cases. The aim of the present study was to study the efficacy and safety of CPT in mainly tumor necrosis factor (TNF)-refractory complicated CD patients. Methods: Patients with refractory CD undergoing CPT were identified in 13 centers of the German IBD Study Group and retrospectively registered...
March 2018: Inflammatory Intestinal Diseases
Xin Ran, Yuhang Li, Guangxin Chen, Shoupeng Fu, Dewei He, Bingxu Huang, Libin Wei, Yuanqing Lin, Yingcheng Guo, Guiqiu Hu
Farrerol, a type of 2, 3-dihydro-flavonoid, is obtained from Rhododendron. Previous studies have shown that Farrerol performs multiple biological activities, such as anti-inflammatory, antibacterial, and antioxidant activity. In this study, we aim to investigate the effect of Farrerol on colonic inflammation and explore its potential mechanisms. We found that the effect of Farrerol was evaluated via the 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis model in mice and found that Farrerol has a protective effect on TNBS-induced colitis...
July 13, 2018: International Journal of Molecular Sciences
Federico Carbone, Giorgia Bodini, Matteo Brunacci, Aldo Bonaventura, Alessandra Vecchiè, Luca Liberale, Mattia Crespi, Isabella Baldissarro, Franco Dallegri, Vincenzo Savarino, Fabrizio Montecucco, Edoardo G Giannini
BACKGROUND: Growing evidence indicates tissue inhibitors of matrix metalloproteinases (TIMPs) as potential players in inflammatory bowel disease (IBD), but, no prospective data are available in IBD remission/relapse. MATERIAL & METHODS: In this prospective pilot study, a cohort of IBD patients (n = 32) was enrolled and treated with monoclonal anti-TNF-α antibodies. Patients were clinically followed up for a median period of 54 weeks. Serum circulating levels of C-reactive protein (CRP), TIMP-1 and -2, matrix metalloproteinase (MMP)-9 and -8, myeloperoxidase (MPO) and neutrophil elastase (NE) were assessed by ELISA at enrolment and at the end of the treatment...
July 16, 2018: European Journal of Clinical Investigation
Peter C Church, Jeffrey Hyams, Frank Ruemmele, Lissy de Ridder, Dan Turner, Anne M Griffiths
Background and Aims: Use of anti-TNF therapies varies internationally. As an initiative of the international Pediatric IBD Network (PIBDNet), we compared global pediatric IBD anti-TNF practice patterns. Methods: Physicians were surveyed about anti-TNF use in Crohn's disease (CD) and ulcerative colitis (UC). Chi-squared, independent samples Mann-Whitney U , or related samples Wilcoxon signed rank tests were used to compare groups. Results: 344 physicians treating pediatric IBD responded from 43 countries (54% North America, 29% Europe, 6% Oceania, 6% Asia, 3% Africa, and 2% South America)...
2018: Canadian Journal of Gastroenterology & Hepatology
Carlos Bernardes, Pedro Russo, Diana Carvalho, Joana Saiote, Jaime Ramos
Introduction: Systemic inflammatory diseases are related to an increased risk of lymphoproliferative disorders. Although inflammatory bowel disease (IBD) was also associated with these conditions, population-based studies failed to demonstrate this relationship, and most studies only identified a very small number of cases. In the last few years, concerns arose regarding the role of thiopurines and tumour necrosis factor-alpha (TNF-α)-blocking agents in the development of lymphoma, influencing therapeutic decisions in IBD patients...
June 2018: GE Portuguese journal of gastroenterology
Kelly C Cushing, Richard Mclean, Keely G McDonald, Jenny K Gustafsson, Kathryn A Knoop, Devesha H Kulkarni, R Balfour Sartor, Rodney D Newberry
Background: Assessing risk of Crohn's disease (CD) recurrence following ileocolic resection (ICR) is necessary to optimize medical management and prevent long-term complications. This study aimed to identify noninvasive markers that could predict postoperative disease activity. Methods: Inclusion criteria were a diagnosis of CD, first ICR, interval colonoscopy, and whole transcriptome array meeting quality control standards. Demographic and clinical data were obtained from the electronic medical record...
July 5, 2018: Inflammatory Bowel Diseases
Fotios S Fousekis, Maria Saridi, Eleni Albani, Fady Daniel, Konstantinos H Katsanos, Ioannis G Kastanioudakis, Dimitrios K Christodoulou
Inflammatory bowel disease (IBD) is a multisystemic disease. The ear is a rare but recognized site of extraintestinal manifestations of IBD. In external ear, the more common manifestations of IBD are pyoderma gangrenosum, metastatic Crohn's disease and relapsing polychondritis and the treatment includes corticosteroids and anti-TNF agents. Sensorineural hearing loss (SNHL) is the most common ear disease in IBD and especially in patients with ulcerative colitis. In most cases of IBD patients with SNHL, the hearing loss is attributable to autoimmune inner ear disease (AIED)...
August 2018: Journal of Clinical Medicine Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"